Chiesi Farmaceutici
Privately held: no public share price
Assets
(7 total)
7Total Assets
4Approved
1Phase 3 / Filed
2Phase 1–2 / Early
7Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Small molecule | Chronic Obstructive Pulmonary DiseaseAsthma | |
Cangrelor(Kengreal) | Approved | P2Y12 receptorSmall molecule | Atherosclerotic Cardiovascular Disease |
Lomitapide(Juxtapid) | Approved | MTPSmall molecule | Homozygous Familial Hypercholesterolemia |
| Approved | Alpha-galactosidase A (GLA / α-Gal A)Protein / enzyme therapeutic | Fabry Disease | |
| Phase 3 | Glucocorticoid receptor; β2-adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary DiseaseAsthma | |
metreleptin(Myalept) | Phase 2 | LeptinProtein / enzyme therapeutic | Obesity |
Melevodopa/carbidopa (Sirio)No recent activity | Phase 1/2 | dopamine precursor · aromatic L-amino acid decarboxylase (AAAD; DOPA decarboxylase)Small molecule | Parkinson's Disease |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
October 2027 (1)
Est. primary completion 2027-10 · NCT05710692 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
US, FDA · FDA · Source ↗
Financial reports
No financial reports recorded.